This is a working overview of gastric juice, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
=== Function === Recent studies have shown in mice, where the SEP15 gene has been silenced the mice subsequently became deficient in SEP15 and were able to inhibit the development of colorectal cancer.
oxidation state Also oxidation number. 1. The degree of oxidation of an individual atom in a chemical compound, measured as the decrease in the number of electrons relative to the atom's naturally occurring elemental state. 2. The hypothetical electric charge (positive, negative, or zero) that an atom would have if all bonds to atoms of different elements were 100% ionic, with no covalent component.
Following its victory in the French and Indian War, Britain began to assert greater control over local affairs in the Thirteen Colonies, resulting in growing political resistance. One of the primary grievances of the colonists was the denial of their rights as Englishmen, particularly the right to representation in the British government that taxed them. To demonstrate their dissatisfaction and resolve, the First Continental Congress met in 1774 and passed the Continental Association, a colonial boycott of British goods enforced by local "committees of safety" that proved effective. The British attempt to then disarm the colonists resulted in the 1775 Battles of Lexington and Concord, igniting the American Revolutionary War. At the Second Continental Congress, the colonies appointed George Washington Commander-in-Chief of the Continental Army, and created a committee that named Thomas Jefferson to draft the Declaration of Independence. Two days after the Second Continental Congress passed the Lee Resolution to create an independent, sovereign nation, the Declaration was adopted on July 4, 1776. The political values of the American Revolution evolved from an armed rebellion demanding reform within an empire to a revolution that created a new social and governing system founded on the defense of liberty and the protection of inalienable natural rights; equality under the law; sovereignty of the people; republicanism over monarchy, aristocracy, and other hereditary political power; civic virtue; and an intolerance of political corruption.
The ASCP Board of Registry (BOR) was established in 1928 as the "Registration Bureau for Technicians" as the first certification agency for clinical laboratory personnel in the US. ASCP was the first professional medical organization to set standards for laboratory professionals, which initially only required a recommendation from a member. Those recommended were subsequently registered with ASCP, hence name the Board of Registry. In 1931, there were two classifications for registrants: Laboratory Technician (L.T.) and Medical Technologist (M.T.). The L.T. designation was granted to all technicians who met the minimum requirements without the examination. The M.T. designations was issued to applicants who met rigid requirement of the Board and were individually elected at each annual meeting. The first certification was issued in 1930 to Paul H. Adams of Fort Wayne, Indiana. In 1933, ASCP began to assess individuals for academic and clinical prerequisites, and those who passed a board examination were granted certification. The initial certifications included a written and practical component. In 1935 the title Medical Technologist (MT) automatically to those certified Laboratory Technicians with college degrees. In 1936, the "Laboratory Technician" designation is retired and subsequent registrants are designated Medical Technologists and the academic requirements were raised to two years of college. In 1938, the Registry was renamed from the Registry of Technicians to the Registry of Medical Technologists.
=== Elongation stages === Loading: Analogous to the starting stage, each module loads its specific amino acid onto its PCP-domain. Condensation: The C-domain catalyzes the amide bond formation between the thioester group of the growing peptide chain from the previous module with the amino group of the current module. The extended peptide is now attached to the current PCP-domain. Condensation-Cyclization: Sometimes the C-domain is replaced by a Cy-domain, which, in addition to the amide bond formation, catalyzes the reaction of the serine, threonine, or cysteine sidechain with the amide-N, thereby forming oxazolidines and thiazolidine, respectively. Epimerization: Sometimes an E-domain epimerizes the innermost amino acid of the peptide chain into the D-configuration. This cycle is repeated for each elongation module.
Sources: en.wikipedia.org
==== κ-opioid receptor ==== In 1997, a group of Australian researchers proposed (based on a study in rats) that oxycodone acts on KORs, unlike morphine, which acts upon MORs. Further research by this group indicated the drug appears to be a high-affinity κ2b-opioid receptor agonist. However, this conclusion has been disputed, primarily on the basis that oxycodone produces effects that are typical of MOR agonists. In 2006, research by a Japanese group suggested the effect of oxycodone is mediated by different receptors in different situations. Specifically in diabetic mice, the KOR appears to be involved in the antinociceptive effects of oxycodone, while in nondiabetic mice, the μ1-opioid receptor seems to be primarily responsible for these effects.
Polatuzumab vedotin, sold under the brand name Polivy, is an antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). Polatuzumab is an antibody that targets CD79b, and vedotin is an agent that inhibits cell division by blocking the polymerisation of tubulin. It was developed by the Genentech subsidiary of Roche. The most common side effects include low levels of white blood cells (neutropenia), platelets (thrombocytopenia) and red blood cells (anemia); nerve damage (peripheral neuropathy); fatigue; diarrhea; fever; decreased appetite; and pneumonia. Polatuzumab vedotin was approved for medical use in the United States in June 2019, in Australia in October 2019, in the European Union in January 2020, and in Canada in November 2020.
=== Organometallic clusters === Organometallic Fe–S clusters include the sulfido carbonyls with the formula Fe2S2(CO)6, H2Fe3S(CO)9, and Fe3S2(CO)9. Compounds are also known that incorporate cyclopentadienyl ligands, such as (C5H5)4Fe4S4.
=== Relationship to land plants === Fossils of isolated spores suggest land plants may have been around as long as 475 million years ago (mya) during the Late Cambrian/Early Ordovician period, from sessile shallow freshwater charophyte algae much like Chara, which likely got stranded ashore when riverine/lacustrine water levels dropped during dry seasons. These charophyte algae probably already developed filamentous thalli and holdfasts that superficially resembled plant stems and roots, and probably had an isomorphic alternation of generations. They perhaps evolved some 850 mya and might even be as early as 1 Gya during the late phase of the Boring Billion.
A gonadotropin release inhibitor is a substance that reduces the secretion of gonadotropins by the anterior pituitary gland. In particular, this means that it reduces the amount of luteinizing hormone (LH) and/or follicle stimulating hormone (FSH) released. Gonadotropins are hormones that signal to the gonads and play a crucial role in the process of gonadal development and function in vertebrates. In birds and mammals, luteinizing hormone (LH) regulates sex steroid production as well as ovulation, whereas follicle stimulating hormone (FSH) promotes spermatogenesis and ovarian follicle maturation. Their release is primarily induced by gonadotropin-releasing hormone (GnRH) (a hypothalamic decapeptide isolated from the mammalian brain in the early 1970s), however several other GnRHs have also been identified in the brains of other vertebrates. Some neurochemicals and peripheral hormones (e.g.gamma-aminobutyric acid (GABA), opiates, gonadal sex steroids, inhibin) can modulate gonadotropin release, but a more specific hypothalamic inhibitory hormone was only identified more recently. In birds, a peptide Gonadotropin-inhibitory hormone was found to suppress gonadotropin release, and later homologous neuropeptides were discovered in mammals, coded by the gene NPVF.
Sources: en.wikipedia.org
Aquasomes are self-assembling nanoparticle drug carrier systems composed of three layers: a ceramic core, an oligomer coat, and a loaded biochemically active molecule. Aquasomes are utilized for targeted drug delivery to achieve specific therapeutic effects, and are biocompatible, biodegradable, and stable. Due to their structure, aquasomes are capable of delivering several types of substrates, and can be used for applications such as delivery of antigens, insulin, and hemoglobin. Aquasomes were first investigated by Kossovsky et al. in 1996 in experiments proposing their use in antigen delivery, drug delivery, and hemoglobin delivery systems. This initial research described aquasomes as self-assembling, with a novel surface modification process allowing the immobilization of drugs on the surface. The research was intended to address the molecular denaturation of polypeptide pharmaceuticals. Kossovsky et al. suggested that this system would be able to combat physical and chemical degradative agents affecting bioactive molecules while preserving the molecular structure of the drug. Since this initial exploration, the understanding of the composition and applications of aquasomes has increased. After each individual layer is synthesized, aquasomes self-assemble into triple-layered particles. The tri-layer structure enables aquasomes to deliver and release poorly soluble drugs in a controlled manner. Delivery of these poorly soluble drugs within aquasomes increases their solubility, bioavailability, and stability.
==== Polysome profiling ==== Polysome profiling is a technique used to characterize the degree of translation of one or more mRNAs. A highly translated mRNA exists as a polysome, meaning it is complexed with multiple ribosomes. mRNAs translated at lower levels are complexed with fewer ribosomes. In polysome profiling, a sucrose gradient is used to separate molecular complexes in a cell lysate based on size. The fractions from the column are analyzed by sequencing or other methods. The translation rate of mRNAs is determined based on their detection and abundance in the fractions of lower and higher molecular weight.
Data loggers typically have slower sample rates. A maximum sample rate of 1 Hz may be considered to be very fast for a data logger, yet very slow for a typical data acquisition system. Data loggers are implicitly stand-alone devices, while typical data acquisition systems must remain tethered to a computer to acquire data. This stand-alone aspect of data loggers implies onboard memory that is used to store acquired data. Sometimes this memory is very large to accommodate many days, or even months, of unattended recording. This memory may be battery-backed static random access memory, flash memory, or EEPROM. Earlier data loggers used magnetic tape, punched paper tape, or directly viewable records such as "strip chart recorders". Given the extended recording times of data loggers, they typically feature a mechanism to record the date and time in a timestamp to ensure that each recorded data value is associated with a date and time of acquisition to produce a sequence of events. As such, data loggers typically employ built-in real-time clocks whose published drift can be an important consideration when choosing between data loggers. Data loggers range from simple single-channel input to complex multi-channel instruments. Typically, the simpler the device the less programming flexibility. Some more sophisticated instruments allow for cross-channel computations and alarms based on predetermined conditions. The newest data loggers can serve web pages, allowing numerous people to monitor a system remotely.
=== United States === The United States Code of Federal Regulations standard for blue cheese specifies a minimum milkfat content of 50 percent, and maximum moisture of 46 percent. Optional ingredients permitted include food coloring to neutralize the yellowish tint of the cheese, benzoyl peroxide bleach, and vegetable wax for coating the rind.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.